## Mamoun M Alhamadsheh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9252611/publications.pdf

Version: 2024-02-01

8 349 5 7 papers citations h-index 9 9 621

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects. Nature Communications, 2022, 13, .	5.8	2
2	Comment to â€`Nelson LT, Paxman RJ, Xu J, etÂal. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma'. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 138-139.	1.4	0
3	Enhancing the Pharmacokinetic Profile of Interleukin 2 through Site-Specific Conjugation to a Selective Small-Molecule Transthyretin Ligand. Journal of Medicinal Chemistry, 2021, 64, 14876-14886.	2.9	5
4	Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents. Molecular Pharmaceutics, 2019, 16, 3237-3252.	2.3	13
5	Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis. Journal of Medicinal Chemistry, 2018, 61, 7862-7876.	2.9	46
6	A biomimetic approach for enhancing the in vivo half-life of peptides. Nature Chemical Biology, 2015, 11, 793-798.	3.9	102
7	AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9992-9997.	3.3	120
8	Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity. Science Translational Medicine, 2011, 3, 97ra81.	5.8	61